Keywords
Abstract
Introduction: Among the most prevalente non-commuicable chronic diseases in the currente scenario, diabetes emerges not only as a disease in isolation but also as a resulto f the countless complications. It is characterized by a syndrome of multipler etiologies, with persistente hyperglycemia due to defects in insulin production or in its action on cells. Objetctive: Analyze the impact os Pharmaceutical Care on the glycemic control of users diagnosed with type 2 diabetes (DM2). Method: Quantitative study that analyzed clinical outcomes such as fasting blood glucose, glycated hemoglobin and microalbuminuria in patients diagnosed with DM2. Results: Of the 17 participants, 11 were famale (64,7%), with a mean age od 60.4 years (sd ± 10.7), ranging between 41 and 709 years. There was a slight reduction in mean HbA1c results after Pharmaceutical care, from 9.9% at baseline to 9.2% at the endo f the study. However, there was a clinically importante improvement in this values in 58.8% of the pacientes, reaching a 53% reduction for one of the followed individuals. Conclusions: Good results were evidenced during the Pharmaceutical care process in user with DM2, where decrease in clinically importante glycated hemoglobina levels were verified, wich influences the reduction of complications resulting from the disease.